Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Salman A. Artificial intelligence and the rebalanced hemostasis of chronic liver disease: From viscoelastic testing to digital twins. World J Hematol 2026; 12(3): 126171 [DOI: 10.5315/wjh.126171]
World J Hematol. Nov 20, 2026; 12(3): 126171 Published online Nov 20, 2026. doi: 10.5315/wjh.126171
Artificial intelligence and the rebalanced hemostasis of chronic liver disease: From viscoelastic testing to digital twins
Ahmed Salman
Ahmed Salman, Department of Internal Medicine, Kasr Alainy School of Medicine, Cairo 11559, Al Qāhirah, Egypt
Author contributions: Salman A conceived the review, designed and performed the literature search, appraised and selected the included studies, prepared the figures and tables, drafted and critically revised the manuscript, and approved the final version submitted for publication.
AI contribution statement: Anthropic Claude (Opus 5, as recorded in the earlier manuscript disclosure) and OpenAI Codex (GPT-6) assisted with language editing, manuscript organization, reference and reported-data checking, and preparation or revision of conceptual figures and tables. The tools helped compare published study details and correct wording. No new research data were generated. The literature-selection process and study conclusions remain the author’s responsibility. AI-assisted statements, citations, numerical summaries, and figures require author verification against the cited sources. The author accepts responsibility for the accuracy, integrity, and originality of the submitted manuscript.
Conflict-of-interest statement: The author declares no conflict of interest.
Corresponding author: Ahmed Salman, FRACP, FRCP, Department of Internal Medicine, Kasr Alainy School of Medicine, 1 Al-Saray Street, Al-Manial, Cairo 11559, Al Qāhirah, Egypt. awea844@gmail.com
Received: July 28, 2026 Revised: September 4, 2026 Accepted: October 16, 2026 Published online: November 20, 2026 Processing time: 114 Days and 12 Hours
Abstract
Chronic liver disease, particularly cirrhosis, produces a fragile, rebalanced hemostatic state. Patients may develop bleeding or thrombosis. The international normalized ratio and platelet count incompletely reflect concurrent procoagulant and anticoagulant changes and poorly predict procedural bleeding. Viscoelastic testing and thrombin-generation assays assess hemostasis more broadly. Randomized trials support viscoelastic testing-guided reductions in blood product use, but these trials do not establish prediction of later bleeding or thrombosis. Machine-learning models address gastrointestinal bleeding outcomes, variceal hemorrhage, portal vein thrombosis (PVT), and transfusion requirements using clinical records, imaging, or elastography. Most cirrhosis models address one outcome, omit direct hemostatic measurements, and have limited external validation. Within the English-language eligibility criteria and focused queries of a PubMed update on July 29, 2026, no adult model jointly estimating future bleeding and PVT in cirrhosis was identified. This structured narrative minireview evaluates the evidence for both outcomes and specifies research requirements for paired-risk models and a possible digital twin of the coagulation-portal axis. Treatment-specific predictions would require additional causal validation.
Core Tip: Bleeding and thrombosis in cirrhosis are competing failures of a fragile hemostatic system; however, published prediction models usually quantify only one failure. Viscoelastic testing describes the current clot behavior more directly than routine tests, but it is rarely incorporated into future-risk models. Before developing a digital twin, a paired-risk model should combine clinical, hemodynamic, and hemostatic data and be tested in external cohorts.